LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS AND CLOSE ASSOCIATES

26 Apr 2024 16:05 CEST

Oslo, Norway, 26 April 2024: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier
today, on 26 April 2024, regarding a share issue of 486,377 shares (the "Offer
Shares") pursuant to a board autorisation granted by the Company's extraordinary
general meeting on 25 April 2024.

As of this date, the Company has been informed that the following close
associates to primary insiders have been allocated Offer Shares, as set out
below:

Hifo Invest AS, a close associate to primary insider, Brynjar Forbergsskog,
subscribed for 38,910 Offer Shares. Hifo Invest AS was allocated 38,910.00 Offer
Shares at a price of NOK 0.10 per share.

Saturn Invest AS, a close associate to primary insider, Brynjar Forbergsskog,
subscribed for 38,910 Offer Shares. Saturn Invest AS was allocated 38,910.00
Offer Shares at a price of NOK 0.10 per share.

Please see the attached forms for further details about the transactions.

Disclosure regulation:
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site

617032_Lytix - mandatory notifications of trade.pdf